Raptiva and Xpovio (80 MG Twice Weekly)
Determining the interaction of Raptiva and Xpovio (80 MG Twice Weekly) and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: The use of efalizumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Efalizumab alone can cause serious infections requiring hospitalization, and the risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (greater than 10 mg/day to 1 mg/kg/day, whichever is less, of prednisone or equivalent for more than 2 weeks), and long-term topical or inhaled corticosteroids. MANAGEMENT: The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated. Patients receiving other immunosuppressive agents should not be treated with efalizumab because of the possibility of excessive immunosuppression. The duration of the period following treatment with efalizumab before one should consider starting other immunosuppressive therapy has not been evaluated. References "Product Information. Raptiva (efalizumab)." Genentech, South San Francisco, CA.
Professional:GENERALLY AVOID: The use of efalizumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Efalizumab alone can cause serious infections requiring hospitalization, and the risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (greater than 10 mg/day to 1 mg/kg/day, whichever is less, of prednisone or equivalent for more than 2 weeks), and long-term topical or inhaled corticosteroids.
MANAGEMENT: The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated. Patients receiving other immunosuppressive agents should not be treated with efalizumab because of the possibility of excessive immunosuppression. The duration of the period following treatment with efalizumab before one should consider starting other immunosuppressive therapy has not been evaluated.
- "Product Information. Raptiva (efalizumab)." Genentech, South San Francisco, CA.
Generic Name: selinexor
Brand name: Xpovio
Synonyms: Xpovio
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Raptiva-Xryliderm
- Raptiva-Xrylix
- Raptiva-Xtampza ER
- Raptiva-Xtandi
- Raptiva-Xtramins
- Raptiva-Xtrelus
- Xpovio (80 MG Twice Weekly)-Rasagiline
- Xpovio (80 MG Twice Weekly)-Rasagiline Mesylate
- Xpovio (80 MG Twice Weekly)-Rasburicase
- Xpovio (80 MG Twice Weekly)-Rasburicase Intravenous
- Xpovio (80 MG Twice Weekly)-Rash Relief Antifungal
- Xpovio (80 MG Twice Weekly)-Rasuvo